Claris Life gets EU nod for anaesthetic drug

02 Jun 2011 Evaluate

Claris Lifesciences Ltd has received an in-principle approval for its anaesthetic drug Propofol in the European Union (EU), enabling the company to process its registration across 25 countries in the Union. Propofol, a flagship product of Claris, is an anaesthetic drug replacing other similar products, as recovery from Propofol is faster.

Europe has one of the most complex procedures for obtaining regulatory approvals. Claris is one of the few companies to have received approval for Propofol in Europe. The market size for Propofol is estimated to be at $750 million worldwide and $150 million in the EU. This registration will benefit Claris as EU is a lucrative market both in terms of revenue and margins.

crackcrack
Peers
Company Name CMP
Redington 216.95
Adani Enterprises 3263.50
Amrapali Industries 15.35
Rashi Peripheral 341.75
Compuage Infocom 3.71
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.